Richard D Baird

Learn More
More women die from breast cancer across the world today than from any other type of malignancy. The clinical course of breast cancer varies tremendously between patients. While some of this variability is explained by traditional clinico-pathological factors (including patient age, tumor stage, histological grade and estrogen receptor status), molecular(More)
This document presents life cycle costs for a low-level radioactive disposal facility and a comparable assured isolation facility. Cost projections were based on general plans and assumptions, including volume projections and operating life, provided by the Connecticut Hazardous waste Management Service, for a facility designed to meet the State's needs.(More)
BACKGROUND Response to treatments is highly heterogeneous in cancer. Increased availability of biomarkers and targeted treatments has led to the need for trial designs that efficiently test new treatments in biomarker-stratified patient subgroups. METHODS We propose a novel Bayesian adaptive randomisation (BAR) design for use in multi-arm phase II trials(More)
The optimized assured isolation facility (AIF) consists of waste shipping containers being placed inside steel-reinforced concrete overpacks, which are, in turn, placed in steel-reinforced concrete vaults without an earthen cover system. The concrete vaults are designed to remain in service for hundreds of years, with the aid of ongoing active maintenance.(More)
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform(More)
PURPOSE Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. METHODS Cohorts A (normal renal function: creatinine clearance [CrCL] >80 mL/min/1.73 m2), B (moderate renal impairment:(More)
  • 1